TY - JOUR
T1 - Endophthalmitis prophylaxis in cataract surgery
T2 - Overview of current practice patterns around the world
AU - Grzybowski, Andrzej
AU - Schwartz, Stephen G.
AU - Matsuura, Kazuki
AU - Tone, Stephan O.
AU - Arshinoff, Steve
AU - Ng, Jonathon Q.
AU - Meyer, Jay J.
AU - Liu, Wu
AU - Jacob, Soosan
AU - Packer, Mark
AU - Lutfiamida, Rifna
AU - Tahija, Sjakon
AU - Roux, Paul
AU - Malyugin, Boris
AU - Urrets-Zavalia, Julio A.
AU - Crim, Nicolas
AU - Esposito, Evangelina
AU - Daponte, Pablo
AU - Pellegrino, Fernando
AU - Graue-Hernandez, Enrique O.
AU - Jimenez-Corona, Aida
AU - Valdez-Garcia, Jorge E.
AU - Hernandez-Camarena, Julio C.
AU - Relhan, Nidhi
AU - Flynn, Harry W.
AU - Ravindran, Ravilla D.
AU - Behnding, Anders
PY - 2017/2/1
Y1 - 2017/2/1
N2 - Background: Acute-onset postoperative endophthalmitis after cataract surgery remains a rare but important cause of visual loss. There is no global consensus regarding the optimal strategies for prophylaxis of endophthalmitis and practices vary substantially around the world, especially with respect to the use of intracameral antibiotics. The European Society of Cataract & Refractive Surgeons in a randomized clinical trial (2007) reported an approximately 5-fold reduction in endophthalmitis rates associated with the use of intracameral cefuroxime. Despite this report, the use of intracameral antibiotics has not been universally adopted. Methods: Various endophthalmitis prophylaxis patterns around the world (including the United States, Canada, Australia/New Zealand, Japan, China, India, Indonesia, South Africa, Argentina, Russia, Sweden and Mexico) are compared. Each contributing author was asked to provide similar information, including endophthalmitis rates based on published studies, current practice patterns, and in some cases original survey data. Various methods were used to obtain this information, including literature reviews, expert commentary, and some new survey data not previously published. Results: Many different practice patterns were reported from around the world, specifically with respect to the use of intracameral antibiotics. Conclusion: There is no worldwide consensus regarding endophthalmitis prophylaxis with cataract surgery.
AB - Background: Acute-onset postoperative endophthalmitis after cataract surgery remains a rare but important cause of visual loss. There is no global consensus regarding the optimal strategies for prophylaxis of endophthalmitis and practices vary substantially around the world, especially with respect to the use of intracameral antibiotics. The European Society of Cataract & Refractive Surgeons in a randomized clinical trial (2007) reported an approximately 5-fold reduction in endophthalmitis rates associated with the use of intracameral cefuroxime. Despite this report, the use of intracameral antibiotics has not been universally adopted. Methods: Various endophthalmitis prophylaxis patterns around the world (including the United States, Canada, Australia/New Zealand, Japan, China, India, Indonesia, South Africa, Argentina, Russia, Sweden and Mexico) are compared. Each contributing author was asked to provide similar information, including endophthalmitis rates based on published studies, current practice patterns, and in some cases original survey data. Various methods were used to obtain this information, including literature reviews, expert commentary, and some new survey data not previously published. Results: Many different practice patterns were reported from around the world, specifically with respect to the use of intracameral antibiotics. Conclusion: There is no worldwide consensus regarding endophthalmitis prophylaxis with cataract surgery.
KW - Cataract surgery
KW - Cataract surgery complications
KW - Endophthalmitis
KW - Endophthalmitis prophylaxis
KW - Intracameral antibiotics
KW - Topical antibiotics
UR - http://www.scopus.com/inward/record.url?scp=85018524874&partnerID=8YFLogxK
U2 - 10.2174/1381612822666161216122230
DO - 10.2174/1381612822666161216122230
M3 - Article
C2 - 27981903
AN - SCOPUS:85018524874
SN - 1381-6128
VL - 23
SP - 565
EP - 573
JO - Current Pharmaceutical Design
JF - Current Pharmaceutical Design
IS - 4
ER -